Cosmo Pharmaceuticals NV (CHIX:COPNZ) Future 3-5Y EPS without NRI Growth Rate : -33.40 (As of May. 28, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate is -33.40.

Competitive Comparison of Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Cosmo Pharmaceuticals NV (CHIX:COPNz) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Cosmo Pharmaceuticals NV Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

CMOPF:USA 0RGI:UK C43:Germany COPN:Switzerland COPN:Austria

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

Cosmo Pharmaceuticals NV Headlines

No Headlines